Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial

Circulation

Volumn 106, Issue 19, 2002, Pages 2422-2427

  Zanchetti, Alberto ^a   Bond, M Gene ^a   Hennig, Michael ^a   Neiss, Albrecht ^a   Mancia, Giuseppe ^a   Dal Palù, Cesare ^a   Hansson, Lennart ^a   Magnani, Bruno ^a   Rahn, Karl Heinz ^a   Reid, John L ^a   Rodicio, Josè ^a   Safar, Michel ^a   Eckes, Lothar ^a   Rizzini, Paolo ^a  

^a Ctro Fisiol Clinica e Ipertensione   (Italy)

Author keywords

Atherosclerosis; Carotid arteries; Drugs; Hypertension; Plaque

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; HYDROCHLOROTHIAZIDE; LACIDIPINE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTERY DIAMETER; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CAROTID ARTERY THROMBOSIS; CLINICAL TRIAL; COMMON CAROTID ARTERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EUROPE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CAROTID ARTERIES; CAROTID ARTERY DISEASES; DIHYDROPYRIDINES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; TIME; TREATMENT OUTCOME; TUNICA INTIMA; TUNICA MEDIA; ULTRASONOGRAPHY;

EID: 0037027501     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000039288.86470.DD     Document Type: Article

References (22)

1. Zanchetti A. The antiatherogenic effects of antihypertensive drugs: Experimental and clinical evidence. Clin Exp Hypertens. 1992;14:307-331.
2. Cominacini L, Garbin U, Pasini AF, et al. Oxidized low-density lipoprotein increases the production of intracellular reactive oxygen species in endothelial cells: Inhibitory effect of lacidipine. J Hypertens. 1998;16:1913-1919.
3. Cominacini L, Pasini AF, Pastorino AM, et al. Comparative effects of different dihydropyridines on the expression of adhesion molecules induced by TNF-alpha on endothelial cells. J Hypertens. 1999;17: 1837-1841.
4. Soma MR, Donetti E. Seregni R. et al. Effect of lacidipine on fatty and proliferative lesions induced in hypercholesterolaemic rabbits. Br J Pharmacol. 1996; 118:215-219.
5. Cristofori P, Lanzoni A, Quartaroli M, et al. The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse. J Hypertens. 2000;18:1429-1436.
6. Zanchetti A. The antiatherogenic effects of antihypertensive treatment: Trials completed and ongoing. Curr Hypertens Rep. 2001;3:350-359.
7. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): A randomized controlled trial. JAMA. 1996;276:785-791.
8. Zanchetti A, Agabiti-Rosei E, Dal Palù C, et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): Results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens. 1998;16:1667-1676.
9. Simon A, Gariépy J, Moyse D, et al. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation. 2001;103:2949-2954.
10. Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation. 1993:87(suppl II):II-56-II-65.
11. Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam Study. Circulation. 1997;96:1432-1437.
12. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998;128:262-269.
13. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults: Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340:14-22.
14. Chambless LE, Folsom AR, Clegg LX, et al. Carotid wall thickness is predictive of incident clinical stroke: The Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2000;151:478-487.
15. Zanchetd A, Bond MG, Hennig M, et al. Risk factors associated with alterations in carotid intima-media thickness in hypertension: Baseline data from the European Lacidipine Study on Atherosclerosis. J Hypertens. 1998;16:949-961.
16. Tang R, Hennig M, Thomasson B, et al. Baseline reproducibility of B-mode ultrasonic measurement of carotid artery intima-media thickness: The European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens. 2000;18:197-201.
17. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963-974.
18. , Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation. 2000;102:1503-1510.
19. MacMahon S, Sharpe N, Gamble G, et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J Am Coll Cardiol. 2000;36:438-443.
20. Lonn EM, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: The Study to Evaluate Carotid Ultrasound changes in patients treated With Ramipril and vitamin E (SECURE). Circulation. 2001;103:919-925.
21. Hedblad B, Wikstrand J, Janzon L, et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the β-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation. 2001;103:1721-1726,
22. Taddei S, Virdis A, Ghiadoni L, et al. Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients. J Hypertens. 2001;19: 1379-1386.